Form 4 for CTNM Contineum Therapeutics, Inc.
Accepted 2026-07-01 19:04:05 ET · period of report 2026-06-30 · accession 0001628280-26-046653 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.07 | +10.0K | 27.2K | +58% | +$10.7K |
| DT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.01 | -10.0K | 17.2K | -37% | -$160.1K |
| DMT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $0.00 | -10.0K | 118.4K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-06-30 | M | A | 7,500 | $1.01 | 24,717 | D | — | — | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. |
| 2 | Common | Class A Common Stock | 2026-06-30 | M | A | 2,500 | $1.26 | 27,217 | D | — | — | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. |
| 3 | Common | Class A Common Stock | 2026-06-30 | S | D | 10,000 | $16.01 | 17,217 | D | — | — | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. (F3) Includes 5,605 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). |
| 4 | Derivative | Stock Option (right to buy) | 2026-06-30 | M | D | 7,500 | $0.00 | 281,930 | D | $1.01 · — to 2030-02-24 | 7,500 Class A Common Stock | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. (F4) Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. |
| 5 | Derivative | Stock Option (right to buy) | 2026-06-30 | M | D | 2,500 | $0.00 | 118,417 | D | $1.26 · — to 2028-11-13 | 2,500 Class A Common Stock | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. (F4) Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. |